a pilot study to investigate the hepcidin levels in patients with rheumatoid arthtitis treated with IL-6R blockade

a pilot study to investigate the hepcidin levels in patients with rheumatoid arthtitis treated with IL-6R blockade - The Hepblock study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33066

Enrollment

Registered

2009-05-29

Start date

2010-04-26

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anemia of chronic disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Moderate to severe active RA Age > 18 treatment with anti-IL-6R

Exclusion criteria

Exclusion criteria: Major surgery within 8 weeks prior to screening Prior history of inflammatory (joint) disease other than RA

Design outcomes

Primary

Measure	Time frame
To determine the hepcidin levels before, 2, 4, 8 and 24 hours after the administration of anti-IL-6R in patients with RA.	—

Secondary

Measure	Time frame
To determine the levels of Iron, transferrin , (calculation of transferrin saturation), ferritin, Hb, CRP and IL-6 before, 2, 4,8 and 24 hours after anti-IL-6R administration in patients with RA.	—

Countries

Netherlands

Outcome results